获得前列腺特异性抗原检测和前列腺癌男性的死亡率
Hari S Iyer1, Benjamin V Stone2,3, Charlotte Roscoe4,5
1Section of Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick.
JAMA network open
|June 4, 2024
概括
一个县的更高的前列腺特异性抗原 (PSA) 查患病率与晚期前列腺癌的几率降低和较低的死亡率有关. 这些关联因患者人口统计和地区而异.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 公共卫生 公共卫生
背景情况:
- 对于前列腺癌的前列腺特异性抗原 (PSA) 查仍然存在争议,对特定的高风险人群有潜在的益处.
- 了解PSA查患病率对前列腺癌结局的影响,对于公共卫生战略至关重要.
研究的目的:
- 调查县级PSA查流行率与前列腺癌结局之间的关联.
- 检查这些关联在不同的社会人口统计学和临床因素中如何变化.
主要方法:
- 一项队列研究利用了来自美国8个州的癌症登记数据,包括被诊断患有前列腺癌的西班牙裔,非西班牙裔黑人和非西班牙裔白人 (2000-2015年).
- 使用行为风险因素监测系统数据 (2004-2012) 估计了县级PSA查流行率.
- 统计模型 (逻辑,考克斯回归,竞争风险) 用于评估与晚期癌症,全因死亡率和前列腺癌特定死亡率的关联.
主要成果:
- 较高的县级PSA查患病率与较低的晚期疾病概率 (AOR,0.86) 和降低全因 (AHR,0.86) 和前列腺癌特异性死亡率 (AHR,0.83) 相关.
- 这些反向关联在西班牙裔男性,老年男性 (≥70岁) 和东北地区的晚期男性中最为明显.
- 对于全因死亡率,在西班牙裔男性,年轻男性,晚期疾病患者和西部地区观察到最强的反向关联.
结论:
- 较高的县级PSA查患病率与改善前列腺癌结局有关,包括减少晚期疾病和死亡率.
- PSA查患病率对结果的影响显示出基于种族和种族,年龄和地理区域的显著差异.
更多相关视频
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.6K
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
651
相关概念视频
01:20Disorders of the Male Reproductive System
393
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
393
01:21Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343